Literature DB >> 18391653

Utility loss and indirect costs after stroke in Sweden.

Peter Lindgren1, Eva-Lotta Glader, Bengt Jönsson.   

Abstract

BACKGROUND: Currently little data exist on the development of quality of life over time in patients suffering from stroke, in particular using instruments that can be adapted in economic studies. The purpose of the study was to assess the utility loss and indirect costs following a stroke in Sweden.
DESIGN: A cross-sectional mail survey.
METHODS: In collaboration with the National Stroke registry (RIKS-STROKE), a questionnaire consisting of the EuroQol-5D and questions regarding the present working status and the status prior to the stroke was mailed to patients below 76 years of age at six participating centres. The questionnaire was mailed to 393 patients in total, divided into groups with 3, 6, 9 or 12 months having passed since the stroke. The EuroQol-5D scores were converted to utility scores using the UK social tariff. Indirect costs were valued according to the average salary+employer contributions.
RESULTS: A total of 275 questionnaires (70%) were returned. Utility scores were similar over time: 0.65, 0.75, 0.63, and 0.67 at 3, 6, 9 and 12 months, respectively. Regression analyses revealed a tendency for lower utility scores among women, but no significant differences overall. Among patients in the working ages, a stroke caused 18.5 work weeks lost, corresponding to an indirect cost of 120,000 Swedish Kronor (SEK) (13,200euro, 95% confidence interval 82,541-160,050 SEK, 9080-17 605euro).
CONCLUSIONS: Stroke causes a significant reduction in utility and causes high indirect costs. A substantial improvement was not noted over time, which is important to consider in economic models.

Entities:  

Mesh:

Year:  2008        PMID: 18391653     DOI: 10.1097/HJR.0b013e3282f37a22

Source DB:  PubMed          Journal:  Eur J Cardiovasc Prev Rehabil        ISSN: 1741-8267


  21 in total

Review 1.  A literature review of indirect costs associated with stroke.

Authors:  Heesoo Joo; Mary G George; Jing Fang; Guijing Wang
Journal:  J Stroke Cerebrovasc Dis       Date:  2014-06-21       Impact factor: 2.136

Review 2.  Cost-effectiveness of statins revisited: lessons learned about the value of innovation.

Authors:  Peter Lindgren; Bengt Jönsson
Journal:  Eur J Health Econ       Date:  2011-04-29

3.  Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland.

Authors:  Jonas Nilsson; Örjan Åkerborg; Gaëlle Bégo-Le Bagousse; Mårten Rosenquist; Peter Lindgren
Journal:  Eur J Health Econ       Date:  2012-05-03

4.  Out-of-pocket costs for childhood stroke: the impact of chronic illness on parents' pocketbooks.

Authors:  Patricia Plumb; Eric Seiber; Michael M Dowling; JoEllen Lee; Timothy J Bernard; Gabrielle deVeber; Rebecca N Ichord; Rachel Bastian; Warren D Lo
Journal:  Pediatr Neurol       Date:  2014-09-28       Impact factor: 3.372

5.  Factors influencing self-reported anxiety or depression following stroke or TIA using linked registry and hospital data.

Authors:  Tharshanah Thayabaranathan; Nadine E Andrew; Monique F Kilkenny; Rene Stolwyk; Amanda G Thrift; Rohan Grimley; Trisha Johnston; Vijaya Sundararajan; Natasha A Lannin; Dominique A Cadilhac
Journal:  Qual Life Res       Date:  2018-08-04       Impact factor: 4.147

6.  Does Emergency Medical Services Transportation Mitigate Post-stroke Discharge Disability? A Prospective Observational Study.

Authors:  Sudha Xirasagar; Yuqi Wu; Khosrow Heidari; Jiera Zhou; Meng-Han Tsai; James W Hardin; Robert Wronski; Dana Hurley; Edward C Jauch; Souvik Sen
Journal:  J Gen Intern Med       Date:  2020-08-31       Impact factor: 5.128

7.  Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke: a systematic review and economic evaluation.

Authors:  Steven J Edwards; Victoria Wakefield; Tracey Jhita; Kayleigh Kew; Peter Cain; Gemma Marceniuk
Journal:  Health Technol Assess       Date:  2020-01       Impact factor: 4.014

8.  Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.

Authors:  Heleen G M van Haalen; Marjolein Pompen; Klas Bergenheim; Phil McEwan; Rebecca Townsend; Marina Roudaut
Journal:  Clin Drug Investig       Date:  2014-02       Impact factor: 2.859

9.  Mapping health outcome measures from a stroke registry to EQ-5D weights.

Authors:  Ola Ghatnekar; Marie Eriksson; Eva-Lotta Glader
Journal:  Health Qual Life Outcomes       Date:  2013-03-07       Impact factor: 3.186

10.  Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model.

Authors:  Matthew R Reynolds; Jonas Nilsson; Orjan Akerborg; Mehul Jhaveri; Peter Lindgren
Journal:  Clinicoecon Outcomes Res       Date:  2013-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.